Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Fentanyl sublingual spray"'
Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label F
Externí odkaz:
http://hdl.handle.net/10150/621765
http://arizona.openrepository.com/arizona/handle/10150/621765
http://arizona.openrepository.com/arizona/handle/10150/621765
Autor:
Neil Singla, Jin Yu, Srinivas Nalamachu, D. Alexander Oh, Richard Rauck, Neha Parikh, Christian Koch, Santosh Vetticaden
Publikováno v:
Current Medical Research and Opinion. 33:1915-1920
Fentanyl sublingual spray offers rapid pain relief in opioid-tolerant cancer patients, and may be useful in acute or post-operative pain. Both opioid-naïve and non-tolerant patients are likely to receive opioids in these settings. Understanding the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2bc0101953b99e089314096a1cc7c7
https://doi.org/10.1080/03007995.2017.1352496
https://doi.org/10.1080/03007995.2017.1352496
Autor:
Ahsan Azhar, Akhila Reddy, Eduardo Bruera, Larry C. Driver, Jane Naberhuis, Ali Haider, Rony Dev, Avery Virgilio, Diane Liu, Kelly Kilgore, David Hui, Shalini Dalal, Farley Hernandez, Liliana Larsson, Suresh K. Reddy
Publikováno v:
J Pain Symptom Manage
Context The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined. Objectives We examined the effect of two doses of prophylactic FSS on exertional dyspnea. Methods In this parallel, dose-finding, double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::916a17859df050619711e7fbecdd1cbd
https://europepmc.org/articles/PMC6754768/
https://europepmc.org/articles/PMC6754768/
Autor:
Owen Dyer
Publikováno v:
BMJ (Clinical research ed.). 365
Two companies that have drawn heavy criticism from legislators investigating some of the drug industry’s worst practices have paid the US government to settle allegations of kickbacks to doctors to prescribe their drugs. Insys Therapeutics paid $22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf4e2b7209c51432206129261d5086f
https://pubmed.ncbi.nlm.nih.gov/31175087
https://pubmed.ncbi.nlm.nih.gov/31175087
Publikováno v:
Pain Management. 6:427-434
175 Background: Sublingual fentanyl spray is indicated for the treatment of breakthrough cancer pain (BTCP) in opioid-tolerant patients receiving around-the-clock (ATC) opioids. This post hoc analysis characterized patients receiving ATC transdermal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272baecd6826b2cfe5cedce3140c77d8
https://doi.org/10.2217/pmt-2015-0009
https://doi.org/10.2217/pmt-2015-0009
Autor:
Eduardo Bruera, David Hui
Publikováno v:
Journal of Pain and Symptom Management. 58:e17-e18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2735d415c888ae63d7da09ed480958a0
https://doi.org/10.1016/j.jpainsymman.2019.07.019
https://doi.org/10.1016/j.jpainsymman.2019.07.019
Publikováno v:
Journal of Pain and Symptom Management. 58:e16-e17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765d441a12c604fd85a83e652d1d16e3
https://doi.org/10.1016/j.jpainsymman.2019.07.020
https://doi.org/10.1016/j.jpainsymman.2019.07.020
Publikováno v:
Pain Practice. 15:554-563
Objectives Breakthrough cancer pain (BTCP) is associated with decreased satisfaction with around-the-clock opioid therapy. This analysis examined patient satisfaction with fentanyl sublingual spray for BTCP during the open-label titration period of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22d2feaa766c52e8ed447c9c0ebebc1
https://doi.org/10.1111/papr.12225
https://doi.org/10.1111/papr.12225
Autor:
Donald R Taylor
Publikováno v:
Clinical Pharmacology : Advances and Applications
Breakthrough cancer pain (BTCP) is defined as a transient exacerbation of pain that arises in patients with otherwise controlled persistent pain. BTCP typically has a rapid onset and relatively short duration, but it causes a significant amount of ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3f1e4bb901fdc298192a38f99158c3
http://europepmc.org/articles/PMC3726301
http://europepmc.org/articles/PMC3726301
Autor:
Richard Rauck, Lowell Reynolds, Jonathan Geach, Neha Parikh, Janet Bull, Larry Dillaha, Morris Scherlis, Lisa Stearns
Publikováno v:
Current Medical Research and Opinion. 28:859-870
A number of transmucosal fentanyl formulations have been developed for the management of breakthrough cancer pain (BTCP). Sublingual delivery of fentanyl, formulated as fentanyl sublingual spray, offers the potential for more rapid and greater absorp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0f2c079b7983a8baea9b0578270808
https://doi.org/10.1185/03007995.2012.683111
https://doi.org/10.1185/03007995.2012.683111